Key highlights
- The Phase 2b DUPLEX-AD study evaluated JNJ-95475939 for atopic dermatitis.
- The study was terminated early due to not meeting efficacy criteria.
- JNJ-5939 was well tolerated during the study.
Study Overview
The Phase 2b DUPLEX-AD study, identified as 95475939ADM2001, assessed the efficacy of JNJ-95475939 (JNJ-5939) for treating moderate to severe atopic dermatitis.
Study Termination
The study was concluded early following an interim analysis, as it did not meet the predefined high-bar efficacy criteria necessary for advancing clinical development.
Tolerability
Despite the early termination, JNJ-5939 was well tolerated by participants during the study.
Commitment to Research
Johnson & Johnson remains dedicated to developing treatments for atopic dermatitis, a chronic condition affecting over 100 million people globally.
